Indian Supreme Court delays Glivec patent hearing until August
This article was originally published in Scrip
Executive Summary
The crucial Indian patent case concerning Novartis' anticancer Glivec (imatinib mesylate) and its rejection due to Section 3(d), a controversial provision in India's patent law, which was to be heard on 10 July will now come up for hearing in the Supreme Court only in August.